AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters

20
4
Favorite

AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters

CNBC2021-04-09

KEY POINTS Australia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment（4）

vxBull
·2021-04-09
Not worried
Reply
3
Report
waihustle
·2021-04-09
When will the pandemic be over?
Reply
3
Report
KaelynGoMoon
·2021-04-09
Like n comment pls
Reply
5
Report
Fold Replies
- Jazling:
  Ok
  2021-04-10
  Reply
  Report
- nujnay:
  pls comment back
  2021-04-09
  Reply
  Report
benlwh
·2021-04-09
Oh good to know!
Reply
1
Report
Fold Replies
- nujnay:
  ??
  2021-04-09
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/1102097181?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2021-04-09 21:17","share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","id":"1102097181","market":"us","top_or_hot":-1,"title":"AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters","media":"CNBC","content":"<div>\n<p>KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html\">Source Link</a>\n\n</div>\n","source":"cnbc_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-09 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AZN.UK","symbol_name":"阿斯利康制药","start_time":0,"source_url":"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html","article_id":"1102097181","we_media_id":null,"thumbnails":[],"rights":{"source":"cnbc_highlight","url":"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.ArticleHeader-headline{#titleStyle#}a{#lv2TextColor#}.ArticleHeader-time, .Author-authorNameAndSocial a{#sourceStyle#;}","selectors":".PageBuilder-pageWrapper","filters":".ArticleHeader-eyebrow, .RelatedTags-relatedTags","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=1102097181","pubTimestamp":1617974277,"sourceInfo":{"source_id":"cnbc_highlight","name":"CNBC"},"weMediaInfo":null,"summary":"KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or aband","collect":0,"end_time":0,"defaultTopTitle":"cnbc.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"AZN.UK":"阿斯利康制药","AZN":"阿斯利康"},"translate_title":"阿斯利康：分析师指出尽管Covid疫苗紧张，但仍有前景","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":0.9,"AZN.UK":0.9},"content_text":"KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to blood clots.\nIt comes after the U.K.’s health and vaccine regulators issued a change of guidance on Wednesday over who should receive the shot, proposing that under-30s get an alternative vaccine.\nIn a research note earlier this week, Jefferies Research Analyst Peter Welford said he had received pushback from clients over a recent decision to upgrade AstraZeneca’s stock to buy, based on the “noise” around the vaccine.\n\nControversy over AstraZeneca’s Covid-19 vaccine has sparked some investor concerns about its stock, according to Jefferies – but it’s not all bad news for the British pharmaceutical company.\nAustralia, the Philippines and the African Union have become the latest to either curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to blood clots.\nIt comes after the U.K.’s health and vaccine regulators issued a change of guidance on Wednesday over who should receive the shot, proposing that under-30s get an alternative vaccine. Both the U.K. and European medicines regulators (the MHRA and EMA, respectively), have emphasized that the benefits of the jab still outweigh the risks, but EU leaders have yet to agree on a joint policy regarding the shots.\nIn a research note earlier this week, Jefferies Research Analyst Peter Welford said he had received pushback from clients over a recent decision to upgrade AstraZeneca’s stock to buy, based on the “noise” around the vaccine.\nThis despite the fact that the company has pledged that the vaccine will be not-for-profit for the “duration of the pandemic,” and will be offered on a non-profit basis in perpetuity to low and middle-income countries.\nThe overall blood clot risk has been estimated at around one in 250,000, and British policymakers and health experts have rushed to defend the vaccinein recent days.\nWelford noted that despite the company’s “remarkable successes” in gaining regulatory approval and ramping up manufacturing of its profit vaccine, the safety concerns raised in Europe are “top of mind for many generalists.”\n“We view FDA Emergency Use Authorization and agreements around dose distribution in U.K./EU as key to shift debate beyond the COVID-19 vaccine, albeit concerns it has been a distraction for management may linger,” he contended.\nThe vaccine has been approved for use in the U.K.,Europe and elsewhere, and hundreds of millions of doses have been ordered by countries across the world. However, it has not yet been granted emergency use authorization in the U.S.\nLooking beyond the shot, Jefferies upgraded AstraZeneca to buy in mid-march, pointing to its “compelling growth profile within EU pharma” and its relative discount based on the expected strategic benefits of its $37 billion acquisition of Alexion Pharmaceuticals, expected to close in the third quarter.\nWelford defended the move by highlighting that the company’s 15x estimated 2022 price-to-earnings ratio — a mechanism for determining whether a company’s stock is fairly valued — is similar to its peers, despite its “leading growth profile.”\nPromising pipeline\nAstraZeneca was trading at £7,337 per share on the London Stock Exchange Friday, and Jefferies has set a price target of £8,850. In Wednesday’s research note, Welford again pointed to multiple catalysts in the pipeline which could propel the stock higher in the coming months.\nPhase three trial data is expected for its breast cancer treatment enhertu is due in the second half of 2021, along with potential approvals for its anifrolumab drug to treat lupus. Jefferies also anticipates approvals for asthma drug tezepelumab in the first half of 2022 after “impressive” phase three data, and a long-delayed approval for anemia candidate roxadustat in the second half of 2021. Updated phase one and two data on lung cancer treatment datopotamab is also expected soon.\nIn a recent note, Morningstar Director of Healthcare Equity Research Damien Conover said of AstraZeneca, “the strong overall innovation seen with the vaccine and pipeline reinforces our conviction in the firm’s wide moat.”\nHe added that AstraZeneca was “making strides in targeting areas of unmet medical need,” projecting that phase three trial data for the company’s farxiga treatment for preserved heart failure was likely to result in approval for the medication.\nConover categorized anifrolumab as “higher risk of approval,” while roxadustat was deemed “medium risk” and tezepelumab “lower risk.”\n“Longer term, we are encouraged by the robustness of the company’s early-stage pipeline, and opportunities to create combinations with Farxiga look well positioned to treat several large cardiometabolic indications where unmet medical need remains high,” Conover said. He added that Morningstar also remains bullish on AstraZeneca’s pipeline for cancer drugs.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":346065885,"gmtCreate":1617975593047,"gmtModify":1704705526260,"author":{"id":"3554974441390212","authorId":"3554974441390212","name":"vxBull","avatar":"https://static.tigerbbs.com/37cb77b20b35271b4b50c825da88849d","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3554974441390212","authorIdStr":"3554974441390212"},"htmlText":"Not worried","listText":"Not worried","text":"Not worried","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/346065885","repostId":1102097181,"repostType":4,"repost":{"id":"1102097181","pubTimestamp":1617974277,"share":"https://ttm.financial/m/news/1102097181?lang=&edition=fundamental","pubTime":"2021-04-09 21:17","market":"uk","language":"en","title":"AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters","url":"https://stock-news.laohu8.com/highlight/detail?id=1102097181","media":"CNBC","summary":"KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or aband","content":"<div>\n<p>KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-09 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN.UK":"阿斯利康制药","AZN":"阿斯利康"},"source_url":"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1102097181","content_text":"KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to blood clots.\nIt comes after the U.K.’s health and vaccine regulators issued a change of guidance on Wednesday over who should receive the shot, proposing that under-30s get an alternative vaccine.\nIn a research note earlier this week, Jefferies Research Analyst Peter Welford said he had received pushback from clients over a recent decision to upgrade AstraZeneca’s stock to buy, based on the “noise” around the vaccine.\n\nControversy over AstraZeneca’s Covid-19 vaccine has sparked some investor concerns about its stock, according to Jefferies – but it’s not all bad news for the British pharmaceutical company.\nAustralia, the Philippines and the African Union have become the latest to either curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to blood clots.\nIt comes after the U.K.’s health and vaccine regulators issued a change of guidance on Wednesday over who should receive the shot, proposing that under-30s get an alternative vaccine. Both the U.K. and European medicines regulators (the MHRA and EMA, respectively), have emphasized that the benefits of the jab still outweigh the risks, but EU leaders have yet to agree on a joint policy regarding the shots.\nIn a research note earlier this week, Jefferies Research Analyst Peter Welford said he had received pushback from clients over a recent decision to upgrade AstraZeneca’s stock to buy, based on the “noise” around the vaccine.\nThis despite the fact that the company has pledged that the vaccine will be not-for-profit for the “duration of the pandemic,” and will be offered on a non-profit basis in perpetuity to low and middle-income countries.\nThe overall blood clot risk has been estimated at around one in 250,000, and British policymakers and health experts have rushed to defend the vaccinein recent days.\nWelford noted that despite the company’s “remarkable successes” in gaining regulatory approval and ramping up manufacturing of its profit vaccine, the safety concerns raised in Europe are “top of mind for many generalists.”\n“We view FDA Emergency Use Authorization and agreements around dose distribution in U.K./EU as key to shift debate beyond the COVID-19 vaccine, albeit concerns it has been a distraction for management may linger,” he contended.\nThe vaccine has been approved for use in the U.K.,Europe and elsewhere, and hundreds of millions of doses have been ordered by countries across the world. However, it has not yet been granted emergency use authorization in the U.S.\nLooking beyond the shot, Jefferies upgraded AstraZeneca to buy in mid-march, pointing to its “compelling growth profile within EU pharma” and its relative discount based on the expected strategic benefits of its $37 billion acquisition of Alexion Pharmaceuticals, expected to close in the third quarter.\nWelford defended the move by highlighting that the company’s 15x estimated 2022 price-to-earnings ratio — a mechanism for determining whether a company’s stock is fairly valued — is similar to its peers, despite its “leading growth profile.”\nPromising pipeline\nAstraZeneca was trading at £7,337 per share on the London Stock Exchange Friday, and Jefferies has set a price target of £8,850. In Wednesday’s research note, Welford again pointed to multiple catalysts in the pipeline which could propel the stock higher in the coming months.\nPhase three trial data is expected for its breast cancer treatment enhertu is due in the second half of 2021, along with potential approvals for its anifrolumab drug to treat lupus. Jefferies also anticipates approvals for asthma drug tezepelumab in the first half of 2022 after “impressive” phase three data, and a long-delayed approval for anemia candidate roxadustat in the second half of 2021. Updated phase one and two data on lung cancer treatment datopotamab is also expected soon.\nIn a recent note, Morningstar Director of Healthcare Equity Research Damien Conover said of AstraZeneca, “the strong overall innovation seen with the vaccine and pipeline reinforces our conviction in the firm’s wide moat.”\nHe added that AstraZeneca was “making strides in targeting areas of unmet medical need,” projecting that phase three trial data for the company’s farxiga treatment for preserved heart failure was likely to result in approval for the medication.\nConover categorized anifrolumab as “higher risk of approval,” while roxadustat was deemed “medium risk” and tezepelumab “lower risk.”\n“Longer term, we are encouraged by the robustness of the company’s early-stage pipeline, and opportunities to create combinations with Farxiga look well positioned to treat several large cardiometabolic indications where unmet medical need remains high,” Conover said. He added that Morningstar also remains bullish on AstraZeneca’s pipeline for cancer drugs.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":346069098,"gmtCreate":1617975244514,"gmtModify":1704705517343,"author":{"id":"3574772025886423","authorId":"3574772025886423","name":"waihustle","avatar":"https://static.tigerbbs.com/ff00b015a4bdda521053764de04de141","vip":1,"crmLevel":7,"crmLevelSwitch":1,"idStr":"3574772025886423","authorIdStr":"3574772025886423"},"htmlText":"When will the pandemic be over?","listText":"When will the pandemic be over?","text":"When will the pandemic be over?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/346069098","repostId":1102097181,"repostType":4,"repost":{"id":"1102097181","pubTimestamp":1617974277,"share":"https://ttm.financial/m/news/1102097181?lang=&edition=fundamental","pubTime":"2021-04-09 21:17","market":"uk","language":"en","title":"AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters","url":"https://stock-news.laohu8.com/highlight/detail?id=1102097181","media":"CNBC","summary":"KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or aband","content":"<div>\n<p>KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-09 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN.UK":"阿斯利康制药","AZN":"阿斯利康"},"source_url":"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1102097181","content_text":"KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to blood clots.\nIt comes after the U.K.’s health and vaccine regulators issued a change of guidance on Wednesday over who should receive the shot, proposing that under-30s get an alternative vaccine.\nIn a research note earlier this week, Jefferies Research Analyst Peter Welford said he had received pushback from clients over a recent decision to upgrade AstraZeneca’s stock to buy, based on the “noise” around the vaccine.\n\nControversy over AstraZeneca’s Covid-19 vaccine has sparked some investor concerns about its stock, according to Jefferies – but it’s not all bad news for the British pharmaceutical company.\nAustralia, the Philippines and the African Union have become the latest to either curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to blood clots.\nIt comes after the U.K.’s health and vaccine regulators issued a change of guidance on Wednesday over who should receive the shot, proposing that under-30s get an alternative vaccine. Both the U.K. and European medicines regulators (the MHRA and EMA, respectively), have emphasized that the benefits of the jab still outweigh the risks, but EU leaders have yet to agree on a joint policy regarding the shots.\nIn a research note earlier this week, Jefferies Research Analyst Peter Welford said he had received pushback from clients over a recent decision to upgrade AstraZeneca’s stock to buy, based on the “noise” around the vaccine.\nThis despite the fact that the company has pledged that the vaccine will be not-for-profit for the “duration of the pandemic,” and will be offered on a non-profit basis in perpetuity to low and middle-income countries.\nThe overall blood clot risk has been estimated at around one in 250,000, and British policymakers and health experts have rushed to defend the vaccinein recent days.\nWelford noted that despite the company’s “remarkable successes” in gaining regulatory approval and ramping up manufacturing of its profit vaccine, the safety concerns raised in Europe are “top of mind for many generalists.”\n“We view FDA Emergency Use Authorization and agreements around dose distribution in U.K./EU as key to shift debate beyond the COVID-19 vaccine, albeit concerns it has been a distraction for management may linger,” he contended.\nThe vaccine has been approved for use in the U.K.,Europe and elsewhere, and hundreds of millions of doses have been ordered by countries across the world. However, it has not yet been granted emergency use authorization in the U.S.\nLooking beyond the shot, Jefferies upgraded AstraZeneca to buy in mid-march, pointing to its “compelling growth profile within EU pharma” and its relative discount based on the expected strategic benefits of its $37 billion acquisition of Alexion Pharmaceuticals, expected to close in the third quarter.\nWelford defended the move by highlighting that the company’s 15x estimated 2022 price-to-earnings ratio — a mechanism for determining whether a company’s stock is fairly valued — is similar to its peers, despite its “leading growth profile.”\nPromising pipeline\nAstraZeneca was trading at £7,337 per share on the London Stock Exchange Friday, and Jefferies has set a price target of £8,850. In Wednesday’s research note, Welford again pointed to multiple catalysts in the pipeline which could propel the stock higher in the coming months.\nPhase three trial data is expected for its breast cancer treatment enhertu is due in the second half of 2021, along with potential approvals for its anifrolumab drug to treat lupus. Jefferies also anticipates approvals for asthma drug tezepelumab in the first half of 2022 after “impressive” phase three data, and a long-delayed approval for anemia candidate roxadustat in the second half of 2021. Updated phase one and two data on lung cancer treatment datopotamab is also expected soon.\nIn a recent note, Morningstar Director of Healthcare Equity Research Damien Conover said of AstraZeneca, “the strong overall innovation seen with the vaccine and pipeline reinforces our conviction in the firm’s wide moat.”\nHe added that AstraZeneca was “making strides in targeting areas of unmet medical need,” projecting that phase three trial data for the company’s farxiga treatment for preserved heart failure was likely to result in approval for the medication.\nConover categorized anifrolumab as “higher risk of approval,” while roxadustat was deemed “medium risk” and tezepelumab “lower risk.”\n“Longer term, we are encouraged by the robustness of the company’s early-stage pipeline, and opportunities to create combinations with Farxiga look well positioned to treat several large cardiometabolic indications where unmet medical need remains high,” Conover said. He added that Morningstar also remains bullish on AstraZeneca’s pipeline for cancer drugs.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":346084079,"gmtCreate":1617975068291,"gmtModify":1704705513599,"author":{"id":"3577222624390363","authorId":"3577222624390363","name":"KaelynGoMoon","avatar":"https://static.tigerbbs.com/9b50f8ca0a8d2a4024495f1ca5401a45","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3577222624390363","authorIdStr":"3577222624390363"},"htmlText":"Like n comment pls","listText":"Like n comment pls","text":"Like n comment pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/346084079","repostId":1102097181,"repostType":4,"repost":{"id":"1102097181","pubTimestamp":1617974277,"share":"https://ttm.financial/m/news/1102097181?lang=&edition=fundamental","pubTime":"2021-04-09 21:17","market":"uk","language":"en","title":"AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters","url":"https://stock-news.laohu8.com/highlight/detail?id=1102097181","media":"CNBC","summary":"KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or aband","content":"<div>\n<p>KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-09 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN.UK":"阿斯利康制药","AZN":"阿斯利康"},"source_url":"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1102097181","content_text":"KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to blood clots.\nIt comes after the U.K.’s health and vaccine regulators issued a change of guidance on Wednesday over who should receive the shot, proposing that under-30s get an alternative vaccine.\nIn a research note earlier this week, Jefferies Research Analyst Peter Welford said he had received pushback from clients over a recent decision to upgrade AstraZeneca’s stock to buy, based on the “noise” around the vaccine.\n\nControversy over AstraZeneca’s Covid-19 vaccine has sparked some investor concerns about its stock, according to Jefferies – but it’s not all bad news for the British pharmaceutical company.\nAustralia, the Philippines and the African Union have become the latest to either curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to blood clots.\nIt comes after the U.K.’s health and vaccine regulators issued a change of guidance on Wednesday over who should receive the shot, proposing that under-30s get an alternative vaccine. Both the U.K. and European medicines regulators (the MHRA and EMA, respectively), have emphasized that the benefits of the jab still outweigh the risks, but EU leaders have yet to agree on a joint policy regarding the shots.\nIn a research note earlier this week, Jefferies Research Analyst Peter Welford said he had received pushback from clients over a recent decision to upgrade AstraZeneca’s stock to buy, based on the “noise” around the vaccine.\nThis despite the fact that the company has pledged that the vaccine will be not-for-profit for the “duration of the pandemic,” and will be offered on a non-profit basis in perpetuity to low and middle-income countries.\nThe overall blood clot risk has been estimated at around one in 250,000, and British policymakers and health experts have rushed to defend the vaccinein recent days.\nWelford noted that despite the company’s “remarkable successes” in gaining regulatory approval and ramping up manufacturing of its profit vaccine, the safety concerns raised in Europe are “top of mind for many generalists.”\n“We view FDA Emergency Use Authorization and agreements around dose distribution in U.K./EU as key to shift debate beyond the COVID-19 vaccine, albeit concerns it has been a distraction for management may linger,” he contended.\nThe vaccine has been approved for use in the U.K.,Europe and elsewhere, and hundreds of millions of doses have been ordered by countries across the world. However, it has not yet been granted emergency use authorization in the U.S.\nLooking beyond the shot, Jefferies upgraded AstraZeneca to buy in mid-march, pointing to its “compelling growth profile within EU pharma” and its relative discount based on the expected strategic benefits of its $37 billion acquisition of Alexion Pharmaceuticals, expected to close in the third quarter.\nWelford defended the move by highlighting that the company’s 15x estimated 2022 price-to-earnings ratio — a mechanism for determining whether a company’s stock is fairly valued — is similar to its peers, despite its “leading growth profile.”\nPromising pipeline\nAstraZeneca was trading at £7,337 per share on the London Stock Exchange Friday, and Jefferies has set a price target of £8,850. In Wednesday’s research note, Welford again pointed to multiple catalysts in the pipeline which could propel the stock higher in the coming months.\nPhase three trial data is expected for its breast cancer treatment enhertu is due in the second half of 2021, along with potential approvals for its anifrolumab drug to treat lupus. Jefferies also anticipates approvals for asthma drug tezepelumab in the first half of 2022 after “impressive” phase three data, and a long-delayed approval for anemia candidate roxadustat in the second half of 2021. Updated phase one and two data on lung cancer treatment datopotamab is also expected soon.\nIn a recent note, Morningstar Director of Healthcare Equity Research Damien Conover said of AstraZeneca, “the strong overall innovation seen with the vaccine and pipeline reinforces our conviction in the firm’s wide moat.”\nHe added that AstraZeneca was “making strides in targeting areas of unmet medical need,” projecting that phase three trial data for the company’s farxiga treatment for preserved heart failure was likely to result in approval for the medication.\nConover categorized anifrolumab as “higher risk of approval,” while roxadustat was deemed “medium risk” and tezepelumab “lower risk.”\n“Longer term, we are encouraged by the robustness of the company’s early-stage pipeline, and opportunities to create combinations with Farxiga look well positioned to treat several large cardiometabolic indications where unmet medical need remains high,” Conover said. He added that Morningstar also remains bullish on AstraZeneca’s pipeline for cancer drugs.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":4003651,"gmtCreate":1618058531115,"gmtModify":1680783564344,"authorId":3566821013640470,"author":{"id":3566821013640470,"idStr":"3566821013640470","authorId":3566821013640470,"name":"Jazling","avatar":"https://static.tigerbbs.com/85e0a83573d9307f57fca9b2baed72af","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.25","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":5,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":346084079,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":3996493,"gmtCreate":1617975695595,"gmtModify":1680783449169,"authorId":3562385137512604,"author":{"id":3562385137512604,"idStr":"3562385137512604","authorId":3562385137512604,"name":"nujnay","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":346084079,"type":1,"supId":0,"prevId":0,"content":"pls comment back","text":"pls comment back","html":"pls comment back"}],"langContent":"EN"},{"id":346089362,"gmtCreate":1617974682056,"gmtModify":1704705503407,"author":{"id":"3573964806596144","authorId":"3573964806596144","name":"benlwh","avatar":"https://static.tigerbbs.com/00e34173af580a6e71b56f222ea75c39","vip":1,"crmLevel":2,"crmLevelSwitch":1,"idStr":"3573964806596144","authorIdStr":"3573964806596144"},"htmlText":"Oh good to know!","listText":"Oh good to know!","text":"Oh good to know!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/346089362","repostId":1102097181,"repostType":4,"repost":{"id":"1102097181","pubTimestamp":1617974277,"share":"https://ttm.financial/m/news/1102097181?lang=&edition=fundamental","pubTime":"2021-04-09 21:17","market":"uk","language":"en","title":"AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters","url":"https://stock-news.laohu8.com/highlight/detail?id=1102097181","media":"CNBC","summary":"KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or aband","content":"<div>\n<p>KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html\">Web Link</a>\n\n</div>\n","source":"cnbc_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca: Analysts point to promising pipeline despite Covid vaccine jitters\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-04-09 21:17 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html><strong>CNBC</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to ...</p>\n\n<a href=\"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"AZN.UK":"阿斯利康制药","AZN":"阿斯利康"},"source_url":"https://www.cnbc.com/2021/04/09/astrazeneca-analysts-point-to-promising-pipeline-despite-covid-vaccine-jitters.html","is_english":true,"share_image_url":"https://static.laohu8.com/72bb72e1b84c09fca865c6dcb1bbcd16","article_id":"1102097181","content_text":"KEY POINTS\n\nAustralia, the Philippines and the African Union have become the latest to curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to blood clots.\nIt comes after the U.K.’s health and vaccine regulators issued a change of guidance on Wednesday over who should receive the shot, proposing that under-30s get an alternative vaccine.\nIn a research note earlier this week, Jefferies Research Analyst Peter Welford said he had received pushback from clients over a recent decision to upgrade AstraZeneca’s stock to buy, based on the “noise” around the vaccine.\n\nControversy over AstraZeneca’s Covid-19 vaccine has sparked some investor concerns about its stock, according to Jefferies – but it’s not all bad news for the British pharmaceutical company.\nAustralia, the Philippines and the African Union have become the latest to either curb or abandon planned purchases of the Oxford University-AstraZeneca coronavirus shot due to possible links to blood clots.\nIt comes after the U.K.’s health and vaccine regulators issued a change of guidance on Wednesday over who should receive the shot, proposing that under-30s get an alternative vaccine. Both the U.K. and European medicines regulators (the MHRA and EMA, respectively), have emphasized that the benefits of the jab still outweigh the risks, but EU leaders have yet to agree on a joint policy regarding the shots.\nIn a research note earlier this week, Jefferies Research Analyst Peter Welford said he had received pushback from clients over a recent decision to upgrade AstraZeneca’s stock to buy, based on the “noise” around the vaccine.\nThis despite the fact that the company has pledged that the vaccine will be not-for-profit for the “duration of the pandemic,” and will be offered on a non-profit basis in perpetuity to low and middle-income countries.\nThe overall blood clot risk has been estimated at around one in 250,000, and British policymakers and health experts have rushed to defend the vaccinein recent days.\nWelford noted that despite the company’s “remarkable successes” in gaining regulatory approval and ramping up manufacturing of its profit vaccine, the safety concerns raised in Europe are “top of mind for many generalists.”\n“We view FDA Emergency Use Authorization and agreements around dose distribution in U.K./EU as key to shift debate beyond the COVID-19 vaccine, albeit concerns it has been a distraction for management may linger,” he contended.\nThe vaccine has been approved for use in the U.K.,Europe and elsewhere, and hundreds of millions of doses have been ordered by countries across the world. However, it has not yet been granted emergency use authorization in the U.S.\nLooking beyond the shot, Jefferies upgraded AstraZeneca to buy in mid-march, pointing to its “compelling growth profile within EU pharma” and its relative discount based on the expected strategic benefits of its $37 billion acquisition of Alexion Pharmaceuticals, expected to close in the third quarter.\nWelford defended the move by highlighting that the company’s 15x estimated 2022 price-to-earnings ratio — a mechanism for determining whether a company’s stock is fairly valued — is similar to its peers, despite its “leading growth profile.”\nPromising pipeline\nAstraZeneca was trading at £7,337 per share on the London Stock Exchange Friday, and Jefferies has set a price target of £8,850. In Wednesday’s research note, Welford again pointed to multiple catalysts in the pipeline which could propel the stock higher in the coming months.\nPhase three trial data is expected for its breast cancer treatment enhertu is due in the second half of 2021, along with potential approvals for its anifrolumab drug to treat lupus. Jefferies also anticipates approvals for asthma drug tezepelumab in the first half of 2022 after “impressive” phase three data, and a long-delayed approval for anemia candidate roxadustat in the second half of 2021. Updated phase one and two data on lung cancer treatment datopotamab is also expected soon.\nIn a recent note, Morningstar Director of Healthcare Equity Research Damien Conover said of AstraZeneca, “the strong overall innovation seen with the vaccine and pipeline reinforces our conviction in the firm’s wide moat.”\nHe added that AstraZeneca was “making strides in targeting areas of unmet medical need,” projecting that phase three trial data for the company’s farxiga treatment for preserved heart failure was likely to result in approval for the medication.\nConover categorized anifrolumab as “higher risk of approval,” while roxadustat was deemed “medium risk” and tezepelumab “lower risk.”\n“Longer term, we are encouraged by the robustness of the company’s early-stage pipeline, and opportunities to create combinations with Farxiga look well positioned to treat several large cardiometabolic indications where unmet medical need remains high,” Conover said. He added that Morningstar also remains bullish on AstraZeneca’s pipeline for cancer drugs.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":3996472,"gmtCreate":1617975596494,"gmtModify":1680783453518,"authorId":3562385137512604,"author":{"id":3562385137512604,"idStr":"3562385137512604","authorId":3562385137512604,"name":"nujnay","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":346089362,"type":1,"supId":0,"prevId":0,"content":"??","text":"??","html":"??"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":20,"commentSize":4,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}